A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
Bladder | Cancer
What is the purpose of this trial?
- To evaluate the overall survival following administration of DN24-02
- To evaluate disease free survival following administration of DN24-02
- To evaluate the safety of DN24-02
- To evaluate the magnitude immune response induced by administration of DN24-02
- To evaluate the magnitude of cumulative CD54 upregulation following administration of DN24-02
Click here for detailed information about who can participate in this trial.
- Dendreon Corporation
- Last Updated:
- Study HIC#: